#United States #TNBC #Foster City #Gilead #Trodelvy

Trodelvy's Positive Outlook for TNBC Treatment

On May 22, Gilead Sciences announced that Trodelvy (sacituzumab govitecan) has received a favorable opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding its use as a treatment for adults with advanced or metastatic triple-negative breast cancer (TNBC), specifically in patients who are unsuitable for PD-1/PD-L1 inhibitors. This recommendation is based on positive outcomes from the ASCENT-03 trial, where Trodelvy showed a statistically significant improvement in progression-free survival (PFS) compared to traditional chemotherapy.

The CHMP's positive opinion is particularly significant for the EU, as it could potentially offer a new first-line treatment option for patients suffering from this challenging subtype of breast cancer. Dr. Javier Cortés, Director at the International Breast Cancer Center in Madrid and Barcelona, emphasizes the critical need for effective early treatment options for many patients diagnosed with metastatic or recurrent TNBC, who often have limited choices.

The ASCENT-03 trial provided critical insights; it indicated that Trodelvy not only alleviated disease progression but also offered a reduction in the risk of death by 38% in patients unresponsive to PD-1/PD-L1 treatment. The results of this trial have set the stage for Gilead to seek FDA approval in the United States for the same indication.

Gilead's Senior Vice President of Oncology Clinical Development, Dr. Mika Kakefuda Derynck, noted, "This positive opinion from the CHMP represents a pivotal moment for TNBC patients across Europe. We hope to receive formal communication from the EMA soon. The unique clinical experience accumulating from Trodelvy's use in late-stage treatments could fundamentally transform first-line approaches for specific TNBC patients, delivering a long-awaited treatment that brings tangible differences in early intervention. Each step forward means providing cancer patients with more choices, resulting in improved quality of life."

The recommendation from CHMP is built upon substantial clinical findings from the ASCENT-03 trial, which underlined the efficacy of Trodelvy as a monotherapy in patients with prior systemic therapy history. The data demonstrated that Trodelvy could significantly outperform traditional chemotherapy options concerning PFS, thus encouraging regulatory bodies to consider its approval for broader use.

Currently, Trodelvy is approved in over 60 countries as a treatment for patients with previously treated metastatic or recurrent TNBC and for those with hormone receptor positive (HR+)/HER2- breast cancer. As usage rises, over 75,000 patients have received this medication since 2020.

Gilead's forward-looking strategy also includes the submission of applications for the combination of Trodelvy and Keytruda (pembrolizumab), targeting PD-L1 positive TNBC patients. The ongoing trials and potential approvals could position Trodelvy as a cornerstone therapy regardless of PD-L1 expression in the treatment of metastatic or recurrent TNBC.

In the broader context, TNBC remains one of the most aggressive forms of breast cancer, accounting for approximately 15% of all breast cancer cases and being predominantly diagnosed among young premenopausal women and among Black and Hispanic women. Due to the absence of targeted hormone or HER2 therapies, treatment options for TNBC patients have been perpetually limited, necessitating innovations and advancements like those offered by Trodelvy.

Conclusion

The promising developments surrounding Trodelvy highlight a significant step forward in the treatment landscape for TNBC, particularly those patients who find themselves with few alternatives due to their ineligibility for existing immunotherapy approaches. As we await formal decisions from the European Commission, the focus on improving patient outcomes and survival rates in TNBC will remain paramount in the fight against this challenging and often devastating disease.